Do analysts prefer VSEE or BACK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VSee Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, VSEE or BACK?

IMAC has lower revenue, but higher earnings than VSee Health. VSee Health is trading at a lower price-to-earnings ratio than IMAC, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VSee Health $14.62M N/A -$14.71M -$0.54 N/A IMAC $72.05K 2.50 -$9.42M -$3.12 N/A

Is VSEE or BACK more profitable?

IMAC has a net margin of 0.00% compared to VSee Health's net margin of -92.36%. IMAC's return on equity of 0.00% beat VSee Health's return on equity. Company Net Margins Return on Equity Return on Assets VSee Health -92.36% -11,636.34% -68.62% IMAC N/A N/A -325.44%

Is BTTX or BACK more profitable?

Company Net Margins Return on Equity Return on Assets Better Therapeutics N/A N/A N/A IMAC N/A N/A -325.44%

Which has better valuation & earnings, UPHL or BACK?

IMAC has lower revenue, but higher earnings than UpHealth. IMAC is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio UpHealth $130M 0.00 -$56.42M $1.47 0.00 IMAC $72.05K 2.50 -$9.42M -$3.12 N/A

Is UPHL or BACK more profitable?

Company Net Margins Return on Equity Return on Assets UpHealth N/A N/A N/A IMAC N/A N/A -325.44%

Which has preferable earnings & valuation, BACK or ACONW?

Aclarion has higher revenue and earnings than IMAC. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IMAC $72.05K 2.50 -$9.42M -$3.12 N/A Aclarion $77.88K N/A N/A N/A N/A

Is BACK or ACONW more profitable?

Company Net Margins Return on Equity Return on Assets IMAC N/A N/A -325.44% Aclarion N/A N/A N/A

Which has stronger earnings and valuation, BACK or DHACW?

Digital Health Acquisition has lower revenue, but higher earnings than IMAC. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IMAC $72.05K 2.50 -$9.42M -$3.12 N/A Digital Health Acquisition N/A N/A N/A N/A N/A

Is BACK or DHACW more profitable?

Company Net Margins Return on Equity Return on Assets IMAC N/A N/A -325.44% Digital Health Acquisition N/A N/A N/A

IMAC (BACK) Competitors

$0.05 0.00 (0.00%)

As of 07/2/2026

Compare

BACK vs. VSEE, BTTX, UPHL, ACONW, and DHACW

Should you buy IMAC stock or one of its competitors? MarketBeat compares IMAC with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IMAC include VSee Health (VSEE), Better Therapeutics (BTTX), UpHealth (UPHL), Aclarion (ACONW), and Digital Health Acquisition (DHACW). These companies are all part of the "healthcare" industry.

How does IMAC compare to VSee Health?

VSee Health (NASDAQ:VSEE) and IMAC (NASDAQ:BACK) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

IMAC has lower revenue, but higher earnings than VSee Health. VSee Health is trading at a lower price-to-earnings ratio than IMAC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VSee Health	$14.62M	N/A	-$14.71M	-$0.54	N/A
IMAC	$72.05K	2.50	-$9.42M	-$3.12	N/A

In the previous week, VSee Health had 1 more articles in the media than IMAC. MarketBeat recorded 1 mentions for VSee Health and 0 mentions for IMAC. IMAC's average media sentiment score of 1.02 beat VSee Health's score of 0.00 indicating that IMAC is being referred to more favorably in the news media.

Company	Overall Sentiment
VSee Health	Neutral
IMAC	Positive

IMAC has a net margin of 0.00% compared to VSee Health's net margin of -92.36%. IMAC's return on equity of 0.00% beat VSee Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VSee Health	-92.36%	-11,636.34%	-68.62%
IMAC	N/A	N/A	-325.44%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VSee Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

1.0% of VSee Health shares are owned by institutional investors. Comparatively, 5.8% of IMAC shares are owned by institutional investors. 19.7% of VSee Health shares are owned by insiders. Comparatively, 12.3% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

VSee Health and IMAC tied by winning 6 of the 12 factors compared between the two stocks.

How does IMAC compare to Better Therapeutics?

Better Therapeutics (NASDAQ:BTTX) and IMAC (NASDAQ:BACK) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Company	Net Margins	Return on Equity	Return on Assets
Better Therapeutics	N/A	N/A	N/A
IMAC	N/A	N/A	-325.44%

Better Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, IMAC has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market.

IMAC has higher revenue and earnings than Better Therapeutics. IMAC is trading at a lower price-to-earnings ratio than Better Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Better Therapeutics	N/A	N/A	-$39.76M	-$0.78	N/A
IMAC	$72.05K	2.50	-$9.42M	-$3.12	N/A

In the previous week, IMAC's average media sentiment score of 1.02 beat Better Therapeutics' score of 0.00 indicating that IMAC is being referred to more favorably in the news media.

Company	Overall Sentiment
Better Therapeutics	Neutral
IMAC	Positive

34.0% of Better Therapeutics shares are owned by institutional investors. Comparatively, 5.8% of IMAC shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by insiders. Comparatively, 12.3% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Better Therapeutics beats IMAC on 5 of the 9 factors compared between the two stocks.

How does IMAC compare to UpHealth?

UpHealth (NYSE:UPHL) and IMAC (NASDAQ:BACK) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

In the previous week, IMAC's average media sentiment score of 1.02 beat UpHealth's score of 0.00 indicating that IMAC is being referred to more favorably in the news media.

Company	Overall Sentiment
UpHealth	Neutral
IMAC	Positive

UpHealth has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, IMAC has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
UpHealth	N/A	N/A	N/A
IMAC	N/A	N/A	-325.44%

IMAC has lower revenue, but higher earnings than UpHealth. IMAC is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UpHealth	$130M	0.00	-$56.42M	$1.47	0.00
IMAC	$72.05K	2.50	-$9.42M	-$3.12	N/A

56.1% of UpHealth shares are owned by institutional investors. Comparatively, 5.8% of IMAC shares are owned by institutional investors. 34.2% of UpHealth shares are owned by insiders. Comparatively, 12.3% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

UpHealth beats IMAC on 6 of the 10 factors compared between the two stocks.

How does IMAC compare to Aclarion?

IMAC (NASDAQ:BACK) and Aclarion (NASDAQ:ACONW) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Company	Net Margins	Return on Equity	Return on Assets
IMAC	N/A	N/A	-325.44%
Aclarion	N/A	N/A	N/A

5.8% of IMAC shares are owned by institutional investors. 12.3% of IMAC shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aclarion has higher revenue and earnings than IMAC.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMAC	$72.05K	2.50	-$9.42M	-$3.12	N/A
Aclarion	$77.88K	N/A	N/A	N/A	N/A

In the previous week, IMAC's average media sentiment score of 1.02 beat Aclarion's score of 0.00 indicating that IMAC is being referred to more favorably in the media.

Company	Overall Sentiment
IMAC	Positive
Aclarion	Neutral

Summary

IMAC beats Aclarion on 3 of the 5 factors compared between the two stocks.

How does IMAC compare to Digital Health Acquisition?

IMAC (NASDAQ:BACK) and Digital Health Acquisition (NASDAQ:DHACW) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Company	Net Margins	Return on Equity	Return on Assets
IMAC	N/A	N/A	-325.44%
Digital Health Acquisition	N/A	N/A	N/A

In the previous week, IMAC's average media sentiment score of 1.02 beat Digital Health Acquisition's score of 0.00 indicating that IMAC is being referred to more favorably in the media.

Company	Overall Sentiment
IMAC	Positive
Digital Health Acquisition	Neutral

5.8% of IMAC shares are owned by institutional investors. 12.3% of IMAC shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Digital Health Acquisition has lower revenue, but higher earnings than IMAC.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMAC	$72.05K	2.50	-$9.42M	-$3.12	N/A
Digital Health Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

IMAC beats Digital Health Acquisition on 4 of the 5 factors compared between the two stocks.

Get IMAC News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BACK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BACK vs. The Competition

Export

Metric	IMAC	Specialty outpatient clinics Industry	Medical Sector	NASDAQ Exchange
Market Cap	$180K	$180K	$7.18B	$12.47B
Dividend Yield	N/A	N/A	2.66%	6.52%
P/E Ratio	-0.02	N/A	28.02	24.70
Price / Sales	2.50	2.50	538.82	97.75
Price / Cash	N/A	N/A	49.26	57.09
Price / Book	-0.07	N/A	10.96	6.46
Net Income	-$9.42M	-$9.42M	$3.57B	$337.01M
7 Day Performance	N/A	N/A	2.12%	1.69%
1 Month Performance	N/A	N/A	5.25%	3.81%
1 Year Performance	N/A	N/A	33.29%	23.90%

IMAC Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BACK IMAC	N/A	$0.05 flat	N/A	-5.0%	$180K	$72.05K	N/A	180
VSEE VSee Health	0.4807 of 5 stars	$0.11 -1.3%	N/A	-90.6%	$397K	$14.46M	N/A	N/A	Short Interest Decrease High Trading Volume
BTTX Better Therapeutics	N/A	N/A	N/A	N/A	$4K	N/A	N/A	40
UPHL UpHealth	N/A	$0.00 -80.0%	N/A	-50.0%	$2K	$130M	N/A	1,750	Gap Down
ACONW Aclarion	N/A	$0.03 -0.4%	N/A	-28.2%	$0.00	$77.88K	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BACK) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IMAC (BACK) Competitors